Agency Supports Broader Access to Innovative Technology in Diabetes Management SILVER SPRING, Md. , Aug. 26, 2024 /PRNewswire/ -- Today, the U.
S. Food and Drug Administration expanded the indications of the Insulet SmartAdjust technology, an interoperable automated glycemic controller previously indicated for the management of type 1 diabetes in individuals two years and older, to also include management of type 2 diabetes in individuals 18 years and older. An interoperable automated glycemic controller is software that automatically adjusts insulin delivery to a person with diabetes by connecting to an alternate controller-enabled insulin pump (ACE pump) and integrated continuous glucose monitor (iCGM).
"The FDA has long worked with the diabetes community to ensure access to additional options and flexibilities for diabetes management," said Michelle Tarver , M.D., Ph.
D., acting director of the FDA's Center for Devices and Radiological Health. "Automated insulin dosing technology has previously been available only for people with type 1 diabetes.
Today's action helps expand access to this important diabetes management tool to millions of adults living in the U.S. with type 2 diabetes.
The FDA is committed to advancing new device innovation that can improve the health and quality of life for people living with chronic diseases that require day-to-day maintenance like diabetes." More than 11% of Americans are diagnosed with diabetes, a condition in which the body does not make.